文献速递淋巴瘤造血干细胞移植与细胞治疗

HIV感染相关淋巴瘤的诊断与治疗

[How I treat lymphomas associated with HIV infection].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2025-01-01

HIV感染相关淋巴瘤总体发病率低,可规范收治的血液肿瘤专科较少。本文从本中心收治的2例患者出发,结合cART联合靶向免疫化疗及完全缓解后尽早行自体造血干细胞移植的临床实践,提出规范化诊治路径,并为新药应用提供参考。

要点

  • 初诊HIV感染相关淋巴瘤患者免疫功能受损,诱导化疗期间感染等并发症发生率高。
  • 复发/难治患者因缺乏新药临床研究,挽救治疗方案极其有限。
  • cART联合靶向免疫化疗达完全缓解后尽早行自体造血干细胞移植可使患者获得长期生存。

核心结论

  • 本文从本中心收治的2例HIV感染相关淋巴瘤患者出发,提出规范化诊治路径,并在新药应用方面为临床医师提供相应参考。

研究设计与样本

  • 本文为基于本中心收治的2例HIV感染相关淋巴瘤患者的诊治经验总结,提出规范化诊治路径。

主要发现

  • HIV感染相关淋巴瘤总体发病率低,且可规范收治该类疾病的血液肿瘤专科较少。
  • 初诊患者因免疫功能受损,诱导治疗过程中感染等并发症发生率高,治疗难度增大。
  • 复发/难治患者因缺乏相应新药临床研究,挽救治疗方案极其有限。
  • 国内外临床实践显示,规范cART联合靶向免疫化疗获得完全缓解后尽早行自体造血干细胞移植可使患者获得长期生存。
  • XPO1抑制剂、免疫检查点抑制剂、抗体药物偶联物、双抗、小分子药物等新药已尝试加入整体治疗方案并获得初步临床数据。

临床怎么用

  • 作者提出规范化诊治路径,并在新药应用方面为临床医师提供相应参考,以提升我国HIV感染相关淋巴瘤诊疗水平。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The overall incidence of lymphomas associated with HIV infection is low, and only few hematological oncology specialties provide standardized treatment. Newly diagnosed patients with impaired immune function have a high incidence of complications, such as infections during induction chemotherapy, which increases treatment difficulties. For patients with relapse/refractory status, salvage treatment options are extremely limited, because new drug clinical trials are lacking. At present, both domestic and international clinical practices have shown that patients with lymphomas associated with HIV infection can achieve long-term survival after standardized combination antiretroviral therapy (cART) with targeted immunochemotherapy, followed by autologous hematopoietic stem cell transplantation (auto-HSCT) immediately after achieving complete remission. In recent years, some new drugs, such as XPO1 inhibitors, immune checkpoint inhibitors, antibody-drug conjugates (ADC drugs), bispecific antibodies, and small-molecule drugs, have been tentatively incorporated into treatment regimens for patients with lymphomas associated with HIV infection, and preliminary clinical data have been obtained. Based on two patients with lymphomas associated with HIV infection who were admitted to our center, this study proposed a standardized diagnostic and treatment pathway and provided corresponding references for clinicians to apply new drugs. The aim of this study was to promote diagnostic and treatment capabilities and improve the survival and quality of life of patients of lymphomas associated with HIV infection in China. 人类免疫缺陷病毒(HIV)感染相关淋巴瘤总体发病率低,且可规范收治该类疾病的血液肿瘤专科较少。对于初诊患者,由于获得性免疫缺陷综合征背景下患者免疫功能受损,诱导治疗过程中感染等并发症发生率高,治疗难度增大;对于复发/难治患者,由于缺乏相应的新药临床研究,故挽救治疗方案极其有限。目前国内外临床实践显示,对于HIV感染相关淋巴瘤患者,规范抗逆转录病毒治疗(cART)联合靶向免疫化疗获得完全缓解后尽早行自体造血干细胞移植可使患者获得长期生存。近年来,一些新药(如XPO1抑制剂、免疫检查点抑制剂、抗体药物偶联物、双抗、小分子药物)也尝试加入HIV感染相关淋巴瘤患者的整体治疗方案中并获得了初步的临床数据。本文从本中心收治的2例HIV感染相关淋巴瘤患者出发,提出规范化诊治路径,并在新药应用方面为临床医师提供相应参考,以提升我国HIV感染相关淋巴瘤诊疗水平,提高患者的生存率及生活质量。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Liu Y, Wang CY. [How I treat lymphomas associated with HIV infection]. Zhonghua Xue Ye Xue Za Zhi. 2025. PMID: 40134193. doi:10.3760/cma.j.cn121090-20241108-00441

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。